A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined,
up to 10 patients may be enrolled in the cohort-expansion phase to better characterize the
safety, tolerability and PK of vantictumab combined with nab-paclitaxel and gemcitabine. Up
to approximately 34 patients may be enrolled into the study.

Inclusion Criteria:

- Signed Informed Consent Form

- Age ≥18 years

- Histologically documented Stage IV ductal adenocarcinoma of the pancreas

- Availability of tumor tissue, either archival FFPE or obtained at study entry through
fresh biopsy

- ECOG performance status of 0 or 1

- Adequate hematologic and end-organ function

- Evaluable or measurable disease per RECIST v1.1

- For women of childbearing potential and men with partners of childbearing potential,
agreement to use two effective forms of contraception

Exclusion Criteria:

- Prior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer

- Prior adjuvant therapy for the treatment of ductal adenocarcinoma of the pancreas

- Known hypersensitivity to any component of study treatments

- Known brain metastases, uncontrolled seizure disorder, or active neurologic disease